 |
4 Diseases |  |
6 Trials |
|
6 Trials |  |
725 News |  |
| «123456789» |
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Review, Journal: Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study. (Pubmed Central) - Apr 26, 2022
Almost all of the bed days after initiation were associated with the index admission during which PP1M was started. In patients stabilised on PP1M and switched to PP3M in normal clinical practice, rehospitalisation is very uncommon and much reduced compared with previous treatments.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
@DrRafaelArroyo El xeplion me ha destruido el sueño aunque ya no me lo pongo. Se corregirá con el tiempo? (Twitter) - Apr 23, 2022
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: Clinical management of medication overdose: Three-monthly paliperidone palimitate injectable medication. (Pubmed Central) - Apr 23, 2022
In patients stabilised on PP1M and switched to PP3M in normal clinical practice, rehospitalisation is very uncommon and much reduced compared with previous treatments. No abstract available
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, HEOR: Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. (Pubmed Central) - Apr 21, 2022
HAL-D, PP1M and PP3M 1-year treatments were similarly effective in preventing relapses and improving quality of life and health satisfaction. All discontinuations in the new 3-monthly antipsychotic treatment were caused by patient refusal to continue it.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Retrospective data, Journal, HEOR: A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China. (Pubmed Central) - Apr 12, 2022
The observed reduction in the number of hospitalizations (t = 2.56, P ≤ 0.01) and inpatient stays (t = 1.73, P < 0.05) and after transition to PP1M resulted in a reduction in hospitalization costs (P < 0.01).Switching from OAPs to PP1M decreased the household workforce burden without increasing clinical healthcare costs. Direct costs were significantly reduced in patients with ≥ 1 inpatient stay in 1 year pre-PP1M treatment with OAPs after the switch, which decreased by improving adherence to therapy and reducing the number and length of hospital stays, suggesting that those patients may benefit after switching to PP1M.
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Trial primary completion date: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia (clinicaltrials.gov) - Apr 11, 2022
P4, N=146, Completed, Sponsor: University of California, Los Angeles
Direct costs were significantly reduced in patients with ≥ 1 inpatient stay in 1 year pre-PP1M treatment with OAPs after the switch, which decreased by improving adherence to therapy and reducing the number and length of hospital stays, suggesting that those patients may benefit after switching to PP1M. Trial primary completion date: May 2021 --> Dec 2021 | Active, not recruiting --> Completed
- ||| paliperidone palmitate ER (LY03010) / Luye Group
New P1 trial: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Apr 10, 2022
P1, N=80, Recruiting, Sponsor: Luye Pharma Group Ltd.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Retrospective data, Journal: Risks of all-cause death and completed suicide in patients with schizophrenia/schizoaffective disorder treated with long-acting injectable or oral antipsychotics: a population-based retrospective cohort study in Taiwan. (Pubmed Central) - Apr 7, 2022
Trial primary completion date: May 2021 --> Dec 2021 | Active, not recruiting --> Completed No abstract available
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Effects of body weight, smoking status and sex on plasma concentrations of once-monthly paliperidone palmitate. (Pubmed Central) - Apr 1, 2022
Our findings suggest that age, sex, smoking or body weight may not substantially affect pharmacokinetic indices of PP1M. The high interindividual variation of plasma concentrations implies that TDM may be helpful to enhance PP1M efficacy and tolerability.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: Initiation of quarterly palmitate paliperidone in French clinical practice: results from the observational, cross-sectional OPTIMUS study. (Pubmed Central) - Mar 26, 2022
The high interindividual variation of plasma concentrations implies that TDM may be helpful to enhance PP1M efficacy and tolerability. PP3M is mostly prescribed in adherent patients with fairly stable schizophrenia, and the longer dosing interval does not substantially affect patient care.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: New approaches to antipsychotic medication adherence - safety, tolerability and acceptability. (Pubmed Central) - Mar 23, 2022
Novel pharmacological delivery methods included different routes of administration of registered medications (such as intramuscular clozapine preparation and transdermal asenapine), modifications of existing compounds (such as 3-monthly injectable formulation of paliperidone palmitate), and increased interest in oral long-acting medication formulations (such as with penfluridol)...The place of each approach is predicated on a personalized approach in each patient and future research could usefully use large comparative studies to establish robust treatment guidelines. The implementation of new and varied approaches to antipsychotic treatment adherence are welcome and have the potential to make a significant impact on morbidity in this often difficult- to- treat population.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Observational data, Retrospective data, Journal: Examining long-acting injectable antipsychotic (depot) medication in the elderly: a 5-year retrospective cross-sectional study evaluating depot use in an Australian psychogeriatric service. (Pubmed Central) - Mar 17, 2022
Lower than usual adult chlorpromazine equivalent daily doses of LAIs were used...LAIs, especially the SGAs, are increasingly used in our service. In combination with a CTO, LAIs are an effective treatment in reducing relapse rates in the elderly.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
One-monthy paliperidone palmitate vs other Long-acting injectable antipsychotics in Psychiatric Home Hospitalitation (E-Poster Gallery) - Mar 16, 2022 - Abstract #EPA2022EPA_967;
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives. (Pubmed Central) - Mar 15, 2022
Most patients, relatives, and mental health professionals prefer PP3M over PP1M. The positive attitudes of all parties may facilitate the more frequent use of PP3M and potentially the clinical outcomes.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Transfer from paliperidone of one-month action to paliperidone of three-month action in schizophrenia spectrum disorders: clinical aspects, pharmacological strategies, therapeutic prediction (Pubmed Central) - Mar 11, 2022
The positive attitudes of all parties may facilitate the more frequent use of PP3M and potentially the clinical outcomes. The results demonstrate the high efficacy of PP-3M and its significant rehabilitation potential, which allows improving the quality of life and social functioning of patients, as well as optimizing the provision of psychiatric care to this contingent of patients, which is of particular importance in the conditions of the COVID-19 pandemic.
- Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Long-Acting Injectable Antipsychotic (LAI) Prescribing Trends during COVID-19 Restrictions in Canada: A Retrospective Observational Study. () - Mar 11, 2022 - Abstract #SIRS2022SIRS_960;
Second-generation LAIs accounted for 96.3% of all LAI new starts with paliperidone palmitate found to be the most prescribed (46.9%), followed by aripiprazole (42%). Anti-epileptics were the most frequent concomitant medication class prescribed, with 20.5% of LAI new starts also having an anti-epileptic drug dispensed.
- risperidone / Generic mfg.
Aerobic Exercise Enhances the Impact of Cognitive Remediation on Positive Symptoms in First-Episode Schizophrenia () - Mar 11, 2022 - Abstract #SIRS2022SIRS_929;
Oral versus PP1M was included as a factor in the model, and baseline Reality Distortion from the BPRS at the randomization baseline point was entered as a covariate. Reality Distortion during the 12-month trial was lower for the CT&E group (mean = 1.9, SD=1.3) compared to the CT group (mean = 2.4, SD=1.6), F(1,54)=6.8, P = .02).
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Real-Life Effectiveness of Transitioning from Paliperidone Palmitate Monthly to Paliperidone Palmitate Three-Monthly Long-Acting Injectable Formulation (Spadolini Pavilion Upper Floor) - Mar 11, 2022 - Abstract #SIRS2022SIRS_658;
The most frequent diagnosis was schizophrenia (63%). Forty-eight composite events occurred during the first 12 months following PP3M initiation, including 33 relapses and 19 discontinuations.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Weight and Metabolic Changes in Patients with Schizophrenia with Paliperidone Palmitate 6 Monthly Versus Paliperidone Palmitate 3 Monthly Treatment: A Post-hoc Analysis (Spadolini Pavilion Upper Floor) - Mar 11, 2022 - Abstract #SIRS2022SIRS_100;
P3
From DB baseline to endpoint, the changes in BW, waist circumference and BMI were numerically higher in the PP3M group vs PP6M group. The mean (SD) increase in BW from MA baseline to DB endpoint were 0.10 (4.959) kg and 0.96 (5.103) kg for the PP6M and PP3M groups, respectively.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Do Long-Acting Injectable Antipsychotics (LAIS) Lower Hospital Utilization and Deliver Superior Economic Outcomes in Schizophrenia (SCZ)? a Systematic Review of Real-World Evidence (RWE) (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1804;
However, RWE shows comparative cost advantages of LAIs relative to one another (newer versus older), and older OAPs is mostly limited. It is also unclear whether economic benefits and lower hospitalization can outweigh higher LAI prices.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Comparing Alternative Paliperidone Formulations for Relapse Prevention in Patients with Schizophrenia: A Cost-Utility Analysis (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_214;
Among paliperidone LAIs, PP3M has a preferable economic value over PP1M and PP6M. However, this conclusion is drawn based on results from clinical trials and might not be generalizable to real-world settings.
- || Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Journal: Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. (Pubmed Central) - Mar 1, 2022
However, this conclusion is drawn based on results from clinical trials and might not be generalizable to real-world settings. No abstract available
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Journal: Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. (Pubmed Central) - Feb 19, 2022
15). Our results show that paliperidone plasma concentrations over injection doses may be associated with patterns of clinical response suggesting potential utility of TDM as part of PP1M-based maintenance treatment.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
EMF baseboard heating and J+J's injectables with sustenna powders? (Twitter) - Feb 18, 2022
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Enrollment closed, Enrollment change: Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) (clinicaltrials.gov) - Feb 14, 2022
P=N/A, N=338, Active, not recruiting, Sponsor: Alkermes, Inc.
Our results show that paliperidone plasma concentrations over injection doses may be associated with patterns of clinical response suggesting potential utility of TDM as part of PP1M-based maintenance treatment. Recruiting --> Active, not recruiting | N=1000 --> 338
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, PK/PD data, Journal: The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data). (Pubmed Central) - Feb 9, 2022
Only 1 patient dropped out after the first PP3M injection. Our preliminary data currently confirm the maintenance of clinical stability shifting from PP1M to PP3M.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice. (Pubmed Central) - Feb 3, 2022
Continuation over 2 years with any PPLAI formulation was 73% (81/111) and relapse was recorded in 9% (10/111). Overall, PP3M was an effective maintenance treatment for schizophrenia after stabilisation on PP1M in a clinical setting.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
PK/PD data, Journal, Adverse drug reaction: Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. (Pubmed Central) - Jan 28, 2022
Our findings did not reveal distinct patterns of paliperidone concentrations in patients with PP1M-related ADRs. However, male patients receiving PP1M every 28 days with C/D values higher than 7.7 (ng/mL)/(mg/day) showed a higher risk for ADRs, implying that therapeutic drug monitoring may be useful in assessing the risk of PP1M-related ADRs.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan. (Pubmed Central) - Jan 27, 2022
The PP1M group also showed better adherence; adjusted odds ratios and 95% CIs were 1.61 (1.22-2.11) (Japan), and 1.92 (1.53-2.41) and 2.25 (1.58-3.23) (China). Persistence and adherence were significantly higher in PP1M users than in oral SGAs users across 3 databases comprising patients in 2 countries in Asia.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal, Real-world evidence: The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting. (Pubmed Central) - Jan 27, 2022
Our results suggest that PP-1M can be considered as an important therapeutic option in patients with ROS. Its use led to a meaningful reduction in the patient's use of hospital services, as well as a significant clinical improvement of psychotic symptoms in our sample.
- ||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Review, Journal, Adverse events: Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. (Pubmed Central) - Jan 15, 2022
The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Retrospective data, Review, HEOR, Real-world evidence: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 7, 2022
The lower medical costs offset the higher pharmacy costs, resulting in a non-significant difference in total healthcare costs. Taken together, these findings provide strong evidence on the clinical and economic benefits of LAI compared with OA for the treatment of schizophrenia in the real world.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal, Real-world evidence: Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. (Pubmed Central) - Dec 25, 2021
We evaluated the use of LAIs antipsychotics [aripiprazole-1-month (A1M); paliperidone-1-month and 3-month (PP1M and PP3M) and biweekly (2w)-LAIs] and their corresponding oral formulations through (1) the number of hospital re-admissions, (2) the number of documented suicidal behaviour/attempts and (3) the use of concomitant benzodiazepines, oral antipsychotics and biperiden...Our results showed that LAIs associated significantly lower suicidal behaviour, reduced the number of hospital admissions, lower diazepam and haloperidol equivalents and mean daily dose of biperiden intake versus oral antipsychotics...In conclusion, LAIs improved clinical outcomes by reducing the need for concomitant treatments and hospital admissions over oral antipsychotics. PP1M and PP3M showed better outcomes versus A1M and biweekly LAIs.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Long-acting injectable antipsychotics: what, when, and how. (Pubmed Central) - Dec 25, 2021
Available LAI formulations in the United States include first-generation antipsychotics (fluphenazine decanoate and haloperidol decanoate), risperidone/paliperidone containing products (risperidone microspheres, paliperidone palmitate, and risperidone subcutaneous), aripiprazole containing products (aripiprazole monohydrate and aripiprazole lauroxil), and olanzapine pamoate...Differences and similarities among the different products are discussed, including guidance regarding optimal treatment selection. Tips are provided to enhance effective patient communication to maximize the likelihood of acceptance of this treatment modality.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal, Real-world evidence: Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain. (Pubmed Central) - Dec 25, 2021
The aim of the present study was to evaluate the use of oral vs. long-acting injectables (LAIs) antipsychotics, as well as, to compare the effectiveness of different LAI antipsychotics [aripiprazole-1-month, paliperidone-1-month (PP1M), paliperidone-3-month (PP3M) and risperidone long-acting injectable (RLAI)] in patients diagnosed with borderline personality disorder (BPD), by evaluating the following clinical outcomes: (1) the number of hospital admissions; (2) the number of documented suicidal behaviour/attempts; and (3) the use of concomitant treatments, including benzodiazepines, oral antipsychotics and biperiden...Moreover, PP1M and PP3M used lower daily dose of diazepam equivalents compared with the aripiprazole-1-month and RLAI treatment groups. In conclusion, the use of LAIs may play a role in the management of BPD.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Journal, Tumor-specific neoantigens, IO biomarker: Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. (Pubmed Central) - Dec 16, 2021
Furthermore, the neoantigen (PPM1 F mutant)-specific TCRs were detected in the tumor-infiltrating T lymphocytes post-vaccination. Our results showed that vaccination with intranodal injection of neoantigen peptide-loaded DCs may have clinical and immunological impacts on cancer treatment.
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Observational data, Journal: Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients. (Pubmed Central) - Dec 16, 2021
The present study shows that older age and female gender are associated with higher paliperidone exposure than younger age and males, respectively. Particularly, older female patients (>50 years) are likely exposed to high concentration and cautious dosing in this subgroup is required.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Once-monthly Paliperidone Palmitate Adherence During the COVID-19 Pandemic ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_151;
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate. (Pubmed Central) - Nov 29, 2021
The focus on adherence issues decreased and the focus on life areas and recovery goals increased. From the clinician perspective, 3-monthly paliperidone palmitate offers patients the potential to remain adherent and improve social functioning.
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Efficacy, Safety and Pharmacokinetics of Paliperidone Palmitate 6-Month Long-Acting Injectable in Patients With Schizophrenia: A Randomized, Double-Blind, Multicenter, Noninferiority Phase 3 Study ([VIRTUAL]) - Nov 28, 2021 - Abstract #ACNP2021ACNP_937;
PK data from the current study as well as the PopPK simulations of concentration-time profiles indicated paliperidone plasma exposures were similar when switching from PP1M (after ≥4 months of treatment) or PP3M (after ≥1 cycle) to PP6M. Thus, PP6M provides consistent medication coverage with just two injections per year and may offer a viable option for maintenance treatment in cases where minimizing the frequency of injections can help meet treatment needs (e.g., patients with limited access to healthcare or medication adherence issues).
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Efficacy, Safety and Pharmacokinetics of Paliperidone Palmitate 6-Month Long-Acting Injectable in Patients With Schizophrenia: A Randomized, Double-Blind, Multicenter, Noninferiority Phase 3 Study (Exhibit Hall C) - Nov 28, 2021 - Abstract #ACNP2021ACNP_642;
PK data from the current study as well as the PopPK simulations of concentration-time profiles indicated paliperidone plasma exposures were similar when switching from PP1M (after ≥4 months of treatment) or PP3M (after ≥1 cycle) to PP6M. Thus, PP6M provides consistent medication coverage with just two injections per year and may offer a viable option for maintenance treatment in cases where minimizing the frequency of injections can help meet treatment needs (e.g., patients with limited access to healthcare or medication adherence issues).
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Factors predicting relapse and treatment discontinuation with paliperidone: 3-monthly long-acting injection - a two-year naturalistic follow-up study. (Pubmed Central) - Nov 24, 2021
Thus, PP6M provides consistent medication coverage with just two injections per year and may offer a viable option for maintenance treatment in cases where minimizing the frequency of injections can help meet treatment needs (e.g., patients with limited access to healthcare or medication adherence issues). Post hoc we examined outcomes in those switched back to one monthly paliperidone (PP1M) long-acting injection...No abstract available
- || paliperidone palmitate ER (LY03010) / Luye Group
Enrollment closed, Trial completion date: Relative Bioavailability of LY03010 Compared to Listed Drug (clinicaltrials.gov) - Nov 22, 2021
P1, N=281, Active, not recruiting, Sponsor: Luye Pharma Group Ltd.
Post hoc we examined outcomes in those switched back to one monthly paliperidone (PP1M) long-acting injection...No abstract available Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Apr 2022
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Retrospective data, Journal: Relapse and frequency of injection of monthly paliperidone palmitate - a retrospective case-control study. (Pubmed Central) - Nov 21, 2021
Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Apr 2022 No abstract available
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Journal: Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients. (Pubmed Central) - Nov 12, 2021
No abstract available No abstract available
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, Retrospective data, Journal, Real-world evidence: The effect of paliperidone palmitate long-acting injectable (PP-LAI) on "non-core" symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the "real world" everyday clinical practice. (Pubmed Central) - Oct 30, 2021
PP-LAI treatment should be offered earlier as possible and was effective on "non-core" symptoms of schizophrenia at follow-up, but had a little effect on alexithymia. However, study' limitations must be considered and future researches are needed to confirm these interesting findings.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. (Pubmed Central) - Oct 29, 2021
Increased all-cause pharmacy costs with PP3M were offset by reduced all-cause medical costs, resulting in overall health care cost-neutrality. Relative to those remaining on PP1M, VHA patients with schizophrenia who transitioned to PP3M experienced improved antipsychotic medication adherence and significantly shorter all-cause inpatient LOS; costs remained neutral.
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion date: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia (clinicaltrials.gov) - Oct 28, 2021
P4, N=170, Active, not recruiting, Sponsor: University of California, Los Angeles
Relative to those remaining on PP1M, VHA patients with schizophrenia who transitioned to PP3M experienced improved antipsychotic medication adherence and significantly shorter all-cause inpatient LOS; costs remained neutral. Trial completion date: Apr 2021 --> Dec 2021
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly? Analysis Based on a Spontaneous Reporting System Database in Japan. (Pubmed Central) - Oct 28, 2021
Trial completion date: Apr 2021 --> Dec 2021 No abstract available
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Reimbursement, Retrospective data, Journal, HEOR, Real-world evidence, Medicaid: Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. (Pubmed Central) - Oct 20, 2021
No abstract available Among patients with a recent schizophrenia-related relapse, PP1M was associated with a lower risk of subsequent relapse while remaining a cost neutral therapeutic option compared to OAAs.